Skip to main content
SpringerLink
Log in

Methodological Concepts: What Could We Know and What Should We Know in Drug Epidemiology?

  • Conference paper
Epidemiological Concepts in Clinical Pharmacology

  • 56 Accesses

Abstract

Epidemiologists and clinical pharmacologists do not always have the same view of things. During the years Professor Kewitz and I have learned to respect the sound scientific principles of both. I am glad to join you in this meeting and to contribute some simple thoughts.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anonymous (1977) Towards a more rational regulation of the development of new medicines. Report of a european workshop held at Sestri Levante, Italy. Eur J Clin Pharmacol 11:233–238

    Article  Google Scholar 

  • Anonymous (1975) Adverse drug reactions in the United States. An analysis of the problem and recommendations for furture approaches. Medicine in the public interest (F.Karch and L. Lasagna) Washington

    Google Scholar 

  • Anonymous (1980) Report of the joint commission on prescription drug use. Final report. Rockville

    Google Scholar 

  • Anonymous (1983) Risk assessment. A study groups report. The Royal Society, London

    Google Scholar 

  • Anonymous (1985) Pharma-Jahresbericht 1984/85. Bundesverband der Pharmazeutischen Industrie.

    Google Scholar 

  • Feinstein AF (1974) Clinical biostatistics XXVIII. The biostatistical problems of pharmaceutical surveillance. Clin Pharmacol Ther 16:110–123

    PubMed  CAS  Google Scholar 

  • Finkle W (1980) Sample size requirement for detection of drug induced disease. In: Joint commission on prescription drug use (ed) Report of joint commission on prescription drug use. Rocheville. App V.

    Google Scholar 

  • Finney DJ (1965) The design and logic of a monitor of drug use. J Chron Dis 18: 77–89

    Article  PubMed  CAS  Google Scholar 

  • Finney DJ (1971) Statistical aspects of monitoring for dangers in drug therapie. Methods of Information in Medicine 10:1–8

    PubMed  CAS  Google Scholar 

  • Finney DJ (1974) Systematic signalling of adverse reactions to drugs. Methods of Information in Medicine 13:1–10

    PubMed  CAS  Google Scholar 

  • Finney DJ (1980) Statistical logic in the monitoring of reactions to therapeutic drugs. In: Inman WHW (ed) Monitoring for drug safety. MTP Press, Lancester, pp 383–400

    Google Scholar 

  • Griffin JP, Darcy PF (1981) Adverse reaction to drugs — the information lag. Side effect of drugs essay 1981. Annual.

    Google Scholar 

  • Hasford J (1983) Die Spontanberichterstattung als Teilsystem der postmarketing surveillance: Gegenwärtiger Stand, Analysen und Empfehlungen. Unpublished manuscript, München

    Google Scholar 

  • Hasford J (1985) Methoden zur Erfassung unerwünschter Arzneimittelwirkungen. In: Dölle W et al. (eds) Grundlagen der Arzneimitteltherapie — Entwicklung, Beurteilung und Anwendung von Arzneimitteln. Wissenschaftsverlag, Mannheim, chap 3.3.1

    Google Scholar 

  • Hasford J (1986) Möglichkeiten und Grenzen der Erfassung von unerwünschten Arzneimittelwirkungen am Beispiel der Antihypertensiva und Lipidsenker: Biometrische Gesichtspunkte. In: Bock, Anschütz (eds) Hugenpott-Symposium 1985

    Google Scholar 

  • Hasford J, Selbmann HK (1983) Effektivität von Mißbildungsregistern. Dtsch Ärzteblatt 80:26–32

    Google Scholar 

  • Hutchinson et al. (1979) An algorithm for the operational assessment of adverse drug reactions II. Demonstration of reproducibility and validity. JAMA 242:633–638

    Article  PubMed  CAS  Google Scholar 

  • Inman WHW (ed) (1980) Monitoring for drug safety. MTP Press, Lancester

    Google Scholar 

  • Inman WHW (1981a) Postmarketing surveillance of adverse drug reactions in general practice I: search for new methods. Br Med J 282:1131–1132

    Article  CAS  Google Scholar 

  • Inman WHW (1981b) Postmarketing surveillance of adverse drug reactions in general practice II: prescription event monitoring in the university of Southampton. Br Med J 282:1216–1217

    Article  CAS  Google Scholar 

  • Jick H, Miettinen OS et al. (1970) Comprehensive drug surveillance. JAMA 213:1455–1460

    Article  PubMed  CAS  Google Scholar 

  • Jones JK (1983) Adverse reaction reporting in the US 1983. In: Grosdanoff P, Schnieders B, Überla K (eds) Arzneimittelsicherheit. BGA-Schrift 1/83, MMW-Verlag, München, pp 43–48

    Google Scholar 

  • Jones JK et al. (1984) Medicaid drug-event data: an emerging tool for evaluation of drug risks. Acta Med Scand [Suppl] 683:127–134

    CAS  Google Scholar 

  • Kramer MS et al. (1979) An algorithm for the operational assessment of adverse drug reactions I. Background, description and introduction for use. JAMA 242:623–632

    Article  PubMed  CAS  Google Scholar 

  • Lassagna L (1984) Techniques for ADR reporting. Skandia International Symposia. Detection and prevention of ADRs. Stockholm, pp 146–151

    Google Scholar 

  • Lawson DH (1980) Intensive monitoring in hospitals I. Boston collaborative drug surveillance program (BCDSP). In: Inman WHW (ed) Monitoring for drug safety. MTP Press, Lancester

    Google Scholar 

  • Lawson DH, Shapiro S et al. (1972) Drug surveillance: problems and challenges. Pediatr Clin North Am 19:117

    Google Scholar 

  • Leventhal et al. (1979) An algorithm for the operational assessment of adverse drug reactions III. Results of tests among clinicians. JAMA 242:1991–1994

    Article  PubMed  CAS  Google Scholar 

  • Levine A, Mandel SPH, Snatamaria A (1977) Pattern signalling in health information monitoring systems. Methods of Information in Medicine 16:138–144

    PubMed  CAS  Google Scholar 

  • Mandel SPH, Levine A, Belena GE (1976) Signalling increase in reporting in international monitoring of adverse reactions to therapeutic drugs. Methods of Information in Medicine 15:1–10

    PubMed  CAS  Google Scholar 

  • Mann JI (1980) Principles and pitfalls in drug epidemiology. In: Inman WHW (ed) Monitoring for drug safety. MTP Press, Lancester, pp 401–415

    Google Scholar 

  • Moir DC (1980) Intensive monitoring in hospitals II. The Aberdeen-Dundee system. In: Inman WHW (ed) Monitoring for drug safety. MTP Press, Lancester

    Google Scholar 

  • Moussa MAA (1978) Statistical problems in monitoring ADRs. Methods of Information in Medicine 17:106–112

    PubMed  CAS  Google Scholar 

  • Musch E, Gugler R (1981) Wechselwirkungen zwischen Arzneimitteln. Dtsch Ärzteblatt 78: 1627–1639

    Google Scholar 

  • Neiß A, Köpeke W, Überla K (1982) Fallzahlschätzungen und Zwischenauswertungen. Internist 23:195–200

    PubMed  Google Scholar 

  • Remington RD (1978) Post-marketing surveillance: a comparison of methods. Publication series of the center for the study of drug development. Boston.

    Google Scholar 

  • Royall BW, Venulet J (1972) Methodology for international drug monitoring. Methods of Information in Medicine 11:75–86

    Google Scholar 

  • Schiesselmann JJ (1982) Case control studies. Oxford University Press, New York

    Google Scholar 

  • Slone D, Jick H et al. (1966) Drug surveillance utilising nurse monitors. Lancet 2:901

    Article  PubMed  CAS  Google Scholar 

  • Skegg DCG (1980) Medical record linkage. In: Inman WHW (ed) Monitoring for drug safety. MTP Press, Lancester

    Google Scholar 

  • Überla K (1980 a) Statistische Gesichtspunkte zur Überwachung unerwünschter Nebenwirkungen zugelassener Medikamente. In: Mehnert H, Stand E (eds) Metformintherapie. Schattauer, Stuttgart, pp 47–58

    Google Scholar 

  • Überla K (1981a) Practical problems in long term clinical trials. In: Bithell JF, Coppi (eds) Proceedings of the European Symposium on medical statistics. Academic, London, pp 173–189

    Google Scholar 

  • Überla K (1981b) Randomized clinical trials — why not? Controlled Clin Trials 1:295–303

    Article  PubMed  Google Scholar 

  • Überla K (1982 a) Wieviele Patienten braucht man für eine Therapiestudie? Gesichtspunkte der klinischen Forschung. MWM 124:437–440

    Google Scholar 

  • Überla K (1982b) Asymmetrien bei der Risiko-Nutzen-Ab wägung in der Medizin. Pharm Ind 44: 1982, 431–436

    Google Scholar 

  • Überla K (1982c) Sicherheit und Risiko im Arzneimittelbereich: Fiktion und Realität. MWM 124: 743–746

    Google Scholar 

  • Überla K (1983) Perspektiven der Erfassung und Bewertung unerwünschter Arzneimittelwirkungen. In: Grosdanoff P, Schnieders B, Überla K (eds) Arzneimittelsicherheit. BGA-Schriften 1/83, MW-Verlag, München, pp 57–59

    Google Scholar 

  • Venning GR (1982) Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarm. Br Med J 284: 249–252

    Article  CAS  Google Scholar 

  • Venning GR (1983) Identification of adverse reactions to new drugs III: alerting process and early warning system. Br Med J 286:458–460

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ISB - Institut für Medizinische Informationsverarbeitung, Statistik und Biomathematik, Ludwig-Maximilians-Universität, Marchioninistr. 15, 8000, München 70, Federal Republic of Germany

    K. Überla

Authors
  1. K. Überla
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Clinical Pharmacology, Klinikum Steglitz of the Free University of Berlin, Hindenburgdamm 30, D-1000, Berlin 45, Federal Republic of Germany

    Helmut Kewitz , Ivar Roots  & Karlheinz Voigt ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin, Heidelberg

About this paper

Cite this paper

Überla, K. (1987). Methodological Concepts: What Could We Know and What Should We Know in Drug Epidemiology?. In: Kewitz, H., Roots, I., Voigt, K. (eds) Epidemiological Concepts in Clinical Pharmacology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71043-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71043-8_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71045-2

  • Online ISBN: 978-3-642-71043-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation